Home › Funds › Slate Path Capital LP › NAMS
Slate Path Capital LP position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Slate Path Capital LP reported holding 319,000 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$10.8M, representing 0.15% of its reported portfolio and ranking #38 among its reported holdings. Slate Path Capital LP has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Slate Path Capital LP's NAMS position evolved
Slate Path Capital LP first disclosed a stake in NAMS in Q4 2024 at 319,000 shares (US$8.2M). The position peaked in Q4 2025 at 319,000 shares, worth US$11.2M. Across 7 filings, Slate Path Capital LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 319,000 shares valued at US$10.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 319.00K | $8.20M | New |
| Q1 2025 | 319.00K | $6.53M | Hold |
| Q2 2025 | 319.00K | $5.78M | Hold |
| Q3 2025 | 319.00K | $9.07M | Hold |
| Q4 2025 | 319.00K | $11.19M | Hold |
| Q1 2026 | 319.00K | $10.21M | Hold |
| Q2 2026 | 319.00K | $10.81M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $287.74M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.21M sh · $74.85M · Q2 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
More on Slate Path Capital LP
FAQ
How long has Slate Path Capital LP held NAMS?
Slate Path Capital LP has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Slate Path Capital LP's current position in NAMS?
As of Q2 2026, Slate Path Capital LP holds 319.00K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $10.81M, representing 0.15% of its reported portfolio and ranking #38.
Has Slate Path Capital LP been buying or selling NAMS?
In the latest 13F filing (Q2 2026), Slate Path Capital LP held unchanged its position in NAMS. The position peaked in Q4 2025 at 319.00K shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.